Breaking News

Tweet TWEET

MEI Pharma Issued European Patent For Lead Mitochondrial Inhibitor Drug Candidate ME-344

   MEI Pharma Issued European Patent For Lead Mitochondrial Inhibitor Drug
                               Candidate ME-344

PR Newswire

SAN DIEGO, Oct. 2, 2012

SAN DIEGO, Oct. 2, 2012 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an
oncology company focused on the clinical development of novel therapies for
cancer, announced today that the European Patent Office has issued a new
patent, European Patent No. 1 794 141 B1, covering the pharmaceutical
composition of the Company's lead mitochondrial inhibitor candidate, ME-344,
and its use in treating cancer. The patent is expected to provide protection
until September 2025.

(Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO)

"This key European patent further reinforces the intellectual property
protection surrounding our portfolio of oncology drug candidates," said Daniel
P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma. "While we
continue to execute our Phase I clinical trial for ME-344 and prepare for our
upcoming Phase II trials, we believe a strong patent estate will help to
provide a clear development path forward and enhance our partnering efforts in
the U.S. and abroad."

MEI Pharma owns exclusive worldwide rights to all of its drug candidates,
including ME-143, ME-344 and Pracinostat. The Company's intellectual property
portfolio now includes 18 issued U.S. patents and more than 150 issued foreign
patents.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused
on the clinical development of novel therapies for cancer. The Company's
clinical development pipeline includes two isoflavone-based drug candidates
derived from its proprietary technology platform, ME-143 and ME-344, and a
potential best-in-class, oral histone deacetylase (HDAC) inhibitor,
Pracinostat. Results from a Phase I dose-escalation trial of lead NADH oxidase
inhibitor ME-143 in heavily treated patients with solid refractory tumors were
presented at the American Society of Clinical Oncology Annual Meeting in June
2012. A Phase I clinical trial of lead mitochondrial inhibitor ME-344 in
patients with solid refractory tumors is ongoing. Pracinostat has been tested
in more than 150 patients in multiple Phase I and exploratory Phase II
clinical trials, including advanced hematologic disorders such as acute
myeloid leukemia, myelodysplastic syndrome and myelofibrosis. For more
information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated
in clinical trials and approved by the FDA as being safe and effective for the
intended use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ materially
from those contained in the forward-looking statements, which are based on
management's current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in clinical trial
results; our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary for
the development, manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our inability to protect
our patents or proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our inability to
operate our business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to gain
market acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice;
and one-time events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these forward-looking
statements.

SOURCE MEI Pharma, Inc.

Website: http://www.meipharma.com
Contact: Pete De Spain, Sr. Director, Investor Relations & Corporate
Communications, +1-858-792-3729, pdespain@meipharma.com
 
Press spacebar to pause and continue. Press esc to stop.